Tags

Type your tag names separated by a space and hit enter

Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
Int J Clin Pharm. 2020 Apr; 42(2):351-354.IJ

Abstract

Background Antiseizure prophylaxis is recommended when high-dose of busulfan is given as part of the conditioning regimens in the allogenic hematopoietic stem cell transplant. Phenytoin has been widely used but its pharmacokinetics and pharmacodynamics profile makes its use complicated. Levetiracetam is a safe, effective and well tolerated antiseizure drug with good results in epileptic patients. Objective To describe our experience using oral (p.o) levetiracetam 1000 mg every 12 h (q12h) as an antiseizure prophylaxis, evaluating its preventive effects and adverse event rates after a high-dose of intravenous (i.v.) busulfan, as part of the conditioning regimen Methods Retrospective study of patients who underwent an allogenic hematopoietic stem cell transplant with a conditioning regimen based on high-dose of busulfan between January and November 2017. Results The study population comprised 36 patients, of whom 18 (50%) had acute myeloid leukemia as diagnosis. No seizures occurred in any patient. Levetiracetam was well tolerated and no serious adverse events were reported. Conclusions Our results suggest that giving levetiracetam at 1000 mg q12h p.o starting 12 h before the administration of i.v. busulfan until 48 h after the last dose, can be used as an alternative in the prevention of busulfan-induced seizures in adults.

Authors+Show Affiliations

Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain. cristianchaguaceda@gmail.com. Pharmacy Department, Consorci Sanitari de Terrassa, Catalonia, Spain. cristianchaguaceda@gmail.com.Pharmacy Department, Consorci Sanitari del Maresme, Mataró, Spain.Department of Hematology, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain.Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain.Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32026356

Citation

Chaguaceda, Cristian, et al. "Oral Levetiracetam for Prevention of Busulfan-induced Seizures in Adult Hematopoietic Cell Transplant." International Journal of Clinical Pharmacy, vol. 42, no. 2, 2020, pp. 351-354.
Chaguaceda C, Aguilera-Jiménez V, Gutierrez G, et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm. 2020;42(2):351-354.
Chaguaceda, C., Aguilera-Jiménez, V., Gutierrez, G., Roura, J., & Riu, G. (2020). Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. International Journal of Clinical Pharmacy, 42(2), 351-354. https://doi.org/10.1007/s11096-020-00977-7
Chaguaceda C, et al. Oral Levetiracetam for Prevention of Busulfan-induced Seizures in Adult Hematopoietic Cell Transplant. Int J Clin Pharm. 2020;42(2):351-354. PubMed PMID: 32026356.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. AU - Chaguaceda,Cristian, AU - Aguilera-Jiménez,Verónica, AU - Gutierrez,Gonzalo, AU - Roura,Judit, AU - Riu,Gisela, Y1 - 2020/02/06/ PY - 2019/06/17/received PY - 2020/01/18/accepted PY - 2020/2/7/pubmed PY - 2021/2/7/medline PY - 2020/2/7/entrez SP - 351 EP - 354 JF - International journal of clinical pharmacy JO - Int J Clin Pharm VL - 42 IS - 2 N2 - Background Antiseizure prophylaxis is recommended when high-dose of busulfan is given as part of the conditioning regimens in the allogenic hematopoietic stem cell transplant. Phenytoin has been widely used but its pharmacokinetics and pharmacodynamics profile makes its use complicated. Levetiracetam is a safe, effective and well tolerated antiseizure drug with good results in epileptic patients. Objective To describe our experience using oral (p.o) levetiracetam 1000 mg every 12 h (q12h) as an antiseizure prophylaxis, evaluating its preventive effects and adverse event rates after a high-dose of intravenous (i.v.) busulfan, as part of the conditioning regimen Methods Retrospective study of patients who underwent an allogenic hematopoietic stem cell transplant with a conditioning regimen based on high-dose of busulfan between January and November 2017. Results The study population comprised 36 patients, of whom 18 (50%) had acute myeloid leukemia as diagnosis. No seizures occurred in any patient. Levetiracetam was well tolerated and no serious adverse events were reported. Conclusions Our results suggest that giving levetiracetam at 1000 mg q12h p.o starting 12 h before the administration of i.v. busulfan until 48 h after the last dose, can be used as an alternative in the prevention of busulfan-induced seizures in adults. SN - 2210-7711 UR - https://www.unboundmedicine.com/medline/citation/32026356/Oral_levetiracetam_for_prevention_of_busulfan_induced_seizures_in_adult_hematopoietic_cell_transplant_ L2 - https://dx.doi.org/10.1007/s11096-020-00977-7 DB - PRIME DP - Unbound Medicine ER -